IRLAB Therapeutics AB (OSTO:IRLAB A) Dividends per Share: kr0.00 (TTM As of Mar. 2026)


OSTO:IRLAB A IRLAB Therapeutics AB OSTO:IRLAB A
36 GF Score
Price kr1.37
GF Value kr11.74
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IRLAB Therapeutics AB Dividends per Share?

IRLAB Therapeutics AB OSTO:IRLAB A -1.43% 36 Dividends per Share is kr0.00 as of Mar. 2026. GuruFocus rates OSTO:IRLAB A with a GF Score™ of 36/100 and a GF Value™ of kr11.74 (Possible Value Trap). The stock has 6 warning signs investors should review.

IRLAB Therapeutics AB's dividends per share for the three months ended in Mar. 2026 was kr0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2026 was 0.00. As of today, IRLAB Therapeutics AB's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

IRLAB Therapeutics AB  (OSTO:IRLAB A) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

IRLAB Therapeutics AB's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2026 )/ EPS without NRI (Q: Mar. 2026 )
=0/ 0.108
=0.00

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRLAB Therapeutics AB Dividends per Share Related Terms

IRLAB Therapeutics AB Dividends per Share Historical Data

* Premium members only.

The historical data trend for IRLAB Therapeutics AB's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRLAB Therapeutics AB Dividends per Share Chart

IRLAB Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividends per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IRLAB Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Dividends per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OSTO:IRLAB A vs VRTX, REGN, ALNY: Dividends per Share Comparison

For the Biotechnology subindustry, IRLAB Therapeutics AB's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRLAB Therapeutics AB Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Dividend Yield % falls into.


OSTO:IRLAB A
36GF Score
IRLAB Therapeutics AB OSTO:IRLAB A
Dividends per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IRLAB Therapeutics AB Dividends per Share Calculation

Dividends paid to per common share.

Frequently Asked Questions Learn more about Dividends per Share →
What does a Dividends per Share of kr0.00 mean?
IRLAB Therapeutics AB (OSTO:IRLAB A) has a Dividends per Share of kr0.00 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on IRLAB Therapeutics AB and its competitors.
Is IRLAB Therapeutics AB's Dividends per Share too high?
IRLAB Therapeutics AB's current Dividends per Share is kr0.00. Overall, IRLAB Therapeutics AB has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's Dividends per Share compare to VRTX and REGN?
IRLAB Therapeutics AB's Dividends per Share of kr0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on IRLAB Therapeutics AB and its competitors. IRLAB Therapeutics AB's current Dividends per Share is kr0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.74, compared to a current price of kr1.37 — trading 88.3% below its estimated fair value. The current Dividends per Share is kr0.00. IRLAB Therapeutics AB's overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current Dividends per Share is kr0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?

Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued. The current stock price of kr1.37 is trading 88.3% below its estimated GF Value™ of kr11.74. GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.

Key valuation signals for OSTO:IRLAB A:

  • Dividends per Share: kr0.00
  • GF Value™: kr11.74 vs. price of kr1.37 (88.3% below fair value)
  • GF Score™: 36/100 with 6 warning signs

No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRLAB Therapeutics AB Business Description

Other Exchanges 6IRA:Germany
Address Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
36GF Score

Get the complete analysis for OSTO:IRLAB A

Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.37
Price
kr11.74
GF Value